338 related articles for article (PubMed ID: 32133402)
1. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy.
Li Z; Gao X; Peng X; May Chen MJ; Li Z; Wei B; Wen X; Wei B; Dong Y; Bu Z; Wu A; Wu Q; Tang L; Li Z; Liu Y; Zhang L; Jia S; Zhang L; Shan F; Zhang J; Wu X; Ji X; Ji K; Wu X; Shi J; Xing X; Wu J; Lv G; Shen L; Ji X; Liang H; Ji J
Sci Adv; 2020 Feb; 6(9):eaay4211. PubMed ID: 32133402
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.
Li Z; Jia Y; Zhu H; Xing X; Pang F; Shan F; Li S; Wang D; Zhao F; Ma T; Wang S; Ji J
Gastric Cancer; 2021 Nov; 24(6):1342-1354. PubMed ID: 34406546
[TBL] [Abstract][Full Text] [Related]
3. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
[TBL] [Abstract][Full Text] [Related]
4. Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.
Jiang D; Shu C; Zhang W; Sun L; Zhang M; He Y; Owen G; Jin W; He D; Deng X; Liu X
Virchows Arch; 2021 Feb; 478(2):231-240. PubMed ID: 32588133
[TBL] [Abstract][Full Text] [Related]
5. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation.
Wang M; Gu H; Qian H; Zhu W; Zhao C; Zhang X; Tao Y; Zhang L; Xu W
Eur J Cancer; 2013 May; 49(8):2010-21. PubMed ID: 23333058
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of changes in the diversity of c-MYC copy number variation after neoadjuvant chemotherapy in breast cancer.
Chung YR; Kim HJ; Kim M; Ahn S; Park SY
Sci Rep; 2018 Nov; 8(1):16668. PubMed ID: 30420657
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib.
Brown JB; Pai RK; Burgess MA; Chennat J; Zureikat AH
J Natl Compr Canc Netw; 2018 Dec; 16(12):1424-1428. PubMed ID: 30545989
[TBL] [Abstract][Full Text] [Related]
9. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
10. Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer.
Li L; Cui Y; Ye L; Zhao Z; Jiang WG; Ji J
Int J Oncol; 2018 Sep; 53(3):1171-1182. PubMed ID: 29956751
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
[TBL] [Abstract][Full Text] [Related]
13. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer.
Hu SB; Liu CH; Wang X; Dong YW; Zhao L; Liu HF; Cao Y; Zhong DR; Liu W; Li YL; Gao WS; Bai CM; Shang ZH; Li XY
World J Surg Oncol; 2019 Jan; 17(1):3. PubMed ID: 30606195
[TBL] [Abstract][Full Text] [Related]
14. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.
Wang S; Chen L; Zhao Q; Rong H; Wang M; Gong W; Zhou J; Wu D; Zhang Z
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1073-82. PubMed ID: 23423487
[TBL] [Abstract][Full Text] [Related]
15. Progress in the development of protein biomarkers of oesophageal and gastric cancers.
Coghlin C; Murray GI
Proteomics Clin Appl; 2016 Apr; 10(4):532-45. PubMed ID: 26582241
[TBL] [Abstract][Full Text] [Related]
16. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of
Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
[TBL] [Abstract][Full Text] [Related]
18. Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?
Goldstein JB; Wu W; Borras E; Masand G; Cuddy A; Mork ME; Bannon SA; Lynch PM; Rodriguez-Bigas M; Taggart MW; Wu J; Scheet P; Kopetz S; You YN; Vilar E
Clin Cancer Res; 2017 Sep; 23(17):5246-5254. PubMed ID: 28522602
[No Abstract] [Full Text] [Related]
19. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Pichler R; Lindner AK; Compérat E; Obrist P; Schäfer G; Todenhöfer T; Horninger W; Culig Z; Untergasser G
Am J Pathol; 2020 Feb; 190(2):442-452. PubMed ID: 31843500
[TBL] [Abstract][Full Text] [Related]
20. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
